Officials at the Marlborough-based molecular diagnostics maker, which is developing tests for colorectal cancer, said the company would retain Grant Thornton LLP instead, according to a filing with the federal Securities and Exchange Commission.
The officials apparently disagreed with an Ernst & Young auditor’s report in Exact Science’s filing dated March 17, 2008, that described uncertainty over its ability to continue as a growing concern due to its escalating debt load.
Outside of that dispute, the officials said, there were “no disagreements of reportable events” over the past two years. Exact Sciences asked Ernst & Young to send a letter to the SEC “stating whether or not it agrees.”
Grant Thornton LLP is the American subsidiary of Grant Thornton International Ltd., a multi-national firm that operates in over 100 countries and employs nearly 30,000 people.